Reply

Diagnosis and Treatment of Obstructive Sleep Apnea Is Key to Achieving Optimal Results After Catheter Ablation of Atrial Fibrillation
The association between obstructive sleep apnea (OSA) and cardiovascular morbidity is well established (1, 2) . In particular, OSA has been shown to potentiate atrial fibrillation (AF) substrate in both animal and human studies (3-7). Our study not only demonstrated that OSA adversely affects the results of AF ablation, but also highlighted the beneficial effect of OSA treatment on AF ablation outcome in this patient population (8) .
Wilcox and colleagues have articulately argued that OSA is an underdiagnosed disease, likely to coexist in a significant proportion of patients with AF. They drew our attention to the current framework with which we define OSA and subsequently use to screen patients. We agree that the current criteria overemphasize respiratory symptomatology and daytime somnolence, which may affect a minority of patients with OSA (9-11). The traditional focus on these symptoms oversimplifies the clinical profile of patients with sleep apnea and thus underestimates its pronounced cardiovascular impact, which may be the heralding symptom.
Threshold criteria for OSA testing in patients with AF should probably be lowered, considering the higher pre-test probability in this patient population. Until new criteria are formalized, we should promote awareness of the association between OSA and AF. Not only is timely identification of OSA in AF patients important in optimizing AF management, but it may mitigate other deleterious cardiovascular effects. We read with great interest the paper by Kosmala et al. (1) in which they report the increased exercise capacity associated with an improved left ventricular (LV) filling pressure in patients with heart failure with preserved ejection fraction (HFpEF) treated with ivabradine. In addition to the mechanisms elegantly discussed by the authors, we would like to point out other potential important contributors to the observed effect.
Heart rate (HR) is one of the major diastolic function determinants. Indeed, an increase in HR may shorten the diastole duration, precluding myocardial relaxation from being complete, and resulting in increased filling pressures. This may be particularly relevant in the setting of slower relaxation, as may be observed in HFpEF patients. Slow incomplete relaxation can be induced by excessive afterload to such an extent that it leads to marked increases in filling pressures. When the ejection fraction is preserved, the effect of afterload is particularly evident and significantly exacerbated at higher pre-loads (2). Moreover, in contrast to normal hearts, the myocardium of heart failure patients may exhibit a flat or negative myocardial relaxation velocity to HR relationship, even at a lower range of HR (3). Consequently, lowering the HR during early exercise would prevent the clinical expression of this HR-dependent relaxation impairment.
Finally, as Reil et al. (4) recently showed, ivabradine decreases arterial elastance through an enhancement of arterial compliance and a reduction in HR. This reduction in global LV afterload could also contribute to the short-term increase in exercise tolerance described in the ivabradine-treated HFpEF patient group.
The absence of a negative lusitropic pharmacological action and the ability to modulate these diastolic function determinants (HR and afterload) make ivabradine a mechanistically very attractive drug in HFpEF treatment. Future clinical trials will give the critical verdict.
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